Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

investorenquiries@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

August 31, Top 20 Shareholders

200831_Top_20_Holders

Categories: News & Announcements 2020, Top 20 ShareholdersBy PharmAust September 1, 2020

Related posts

Top 20 Shareholders December 2022
January 1, 2023

Top 20 Shareholders November 2022
December 1, 2022

Top 20 Shareholders October 2022
November 1, 2022

Top 20 Shareholders
September 30, 2022

Top 20 Shareholders
August 1, 2022

July 1, Top 20 Shareholders
July 1, 2022

Recent Articles

Canine Cancer Trial Update
March 27, 2023
Free Biotech & Nutrition Investor Webinar
March 17, 2023
First Patient of Cohort 2 Dosed in MND Trial 3 market sensitive
February 20, 2023
PharmAust canine trial update 18 market sensitive
February 10, 2023

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

Retweet on Twitter PharmAust Retweeted

PharmAust @pharmaust ·

30 Mar

PharmAust (ASX:PAA) completes enrolment of second patient cohort in MND/ALS trial https://themarketherald.com.au/pharmaust-asxpaa-completes-enrolment-of-second-patient-cohort-in-mnd-als-trial-2023-03-30/ via @themarketherald

Reply on Twitter 1641338317286543360 Retweet on Twitter 1641338317286543360 3 Like on Twitter 1641338317286543360 11 Twitter 1641338317286543360

Retweet on Twitter PharmAust Retweeted

PharmAust @pharmaust ·

30 Mar

PharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease market

https://stockhead.com.au/health/pharmaust-completes-patient-enrolment-for-mpl-trial-with-sights-on-us3-6-billion-motor-neurone-disease-market/

Reply on Twitter 1641272193236758529 Retweet on Twitter 1641272193236758529 5 Like on Twitter 1641272193236758529 17 Twitter 1641272193236758529

PharmAust @pharmaust ·

11h

MND trial completes enrolment of 'Cohort 2' and prepares for interim analysis
Via @BiotechDispatch
https://biotechdispatch.com.au/news/mnd-trial-completes-enrolment-of-cohort-2-and-prepares-for-inter

Reply on Twitter 1641571161678151680 Retweet on Twitter 1641571161678151680 2 Like on Twitter 1641571161678151680 9 Twitter 1641571161678151680

Load More

Copyright © 2023 PharmAust. All rights reserved.

nil

Website Design & Digital Marketing Perth by Total Click Solutions